Mid-21st century. A child in Singapore receives the first anti-aging gene therapy injection. No symptoms of disease. No acute diagnosis. Just one goal: to correct biological signs of aging from the start. Doctors expect him to live until 120 years old—and still walk without a cane at 105. This is not a movie script. It is data from preclinical trials, phase I protocols, and fundamental changes in global disease classification.
CRISPR is no longer for diseases—but for cellular clocks
CRISPR-Cas9 has surpassed traditional genetic treatment. At Harvard and Broad Institute, scientists are now editing *epigenomes*, not DNA itself—reactivating naturally dying methylation 'switches' with age. Mice that underwent epigenetic therapy lived 25% longer *and* showed brain, liver, and muscle function equivalent to young animals. Human trials for progeria—rapid aging syndrome—are underway in Boston and London. Early results: reduced aging biomarkers in blood within less than six months.
Senolytics work more crudely: killing old cells that don't die but also don't function—'zombie' cells that flood tissues with toxic substances. Dasatinib and quercetin, combined, reduced the burden of senescent cells in osteoarthritis patients by 40% in phase II trials. Unity Biotechnology no longer talks about 'symptom reduction.' They measure 'cartilage structural recovery'—and the results are visible on MRI.
Metformin is no longer for diabetes—it's for lifespan
Metformin, a diabetes drug since the 1950s, is now in large-scale clinical trials as the *first* drug tested specifically for aging—not as an adjunct, but as a primary therapy. The TAME (Targeting Aging with Metformin) project involves 3,000 people aged 65–79. They are not diagnosed with diabetes. They were selected because of high risk of developing *several* age-related diseases—such as heart disease, diabetes, or dementia—within five years. If TAME succeeds, the FDA will recognize 'aging' as a legitimate clinical indication. Not a metaphor. Not a label. But a diagnosis that can be coded, paid for by insurance, and treated.
Rapamycin extends mouse lifespan by 30%, but its side effects—immune suppression, insulin resistance—are too costly for humans. Hence, rapalogs: adjusted versions that retain anti-aging effects without compromising the body's defense system. NMN, however, remains in a gray area: popular among biohackers, sold over-the-counter in the US, but no controlled human trials have shown increased lifespan—only increased NAD+ levels in blood. That is not a promise. It is just a biological marker.
100 years is no longer 'the end'. It is the beginning of the third act.
Imagine: you retire at 72. Then live another 48 years—longer than your working life. Pension systems designed for 15 years post-retirement now must accommodate three decades. Health insurance no longer counts 'age 80 risk', but 'age 110 risk'—with data not yet available.
Japan is no longer a warning. It is a real-life laboratory. In Tokyo, 28% of the population is over 65. There, trains have installed 'stop longer' buttons at stations; hospitals train doctors to diagnose *age-related depression* not as a complication, but as a primary disease. But access is not equal. One dose of experimental epigenetic therapy in Zurich costs RM420,000. One course of senolytic therapy in Los Angeles: RM85,000. Without global regulation, 'longevity' will become a luxury—no longer a human right.
Death is no longer a question of 'when'. It is a question of 'what we leave behind'
Some religious scholars and cultural thinkers strongly reject classifying aging as a disease. Not because they oppose science—but because they fear it erases the existential dimension of death: the motivation to do good, the value of time, and the gratitude for today. WHO has recently included 'aging' in ICD-11—not as a disease code, but as a *supplementary code* for 'age-related conditions'. A small step. But enough to open the door to research funding, insurance, and health policy.
Deeper still: the psychology of long life. If humans can live 120 years, are the first 30 years still 'learning time'? Are the next 50 years 'working time'? Or will we see three careers, two marriages, four residences—all within one lifetime? Geriatric psychologist Laura Carstensen shows that older people actually make better long-term decisions, are more empathetic, and less impulsive. Not because they are 'wise,' but because their brains have discarded what is unimportant. Longevity is not a guarantee of wisdom—but it gives space for wisdom to develop.
What will really matter in two years
Three things will determine the direction of this revolution:
The real goal is not 120 years. It is *30 additional healthy years*—without dementia, without loss of mobility, without relying on others. Scientists call it 'compressing morbidity': shrinking the period of illness at the end of life until it almost disappears. Not delaying death. But ensuring death comes after life has truly ended.